Home/InflaRx/Prof. Renfeng Guo, M.D.
PR

Prof. Renfeng Guo, M.D.

Chief Scientific Officer and Founder

InflaRx

InflaRx Pipeline

DrugIndicationPhase
Vilobelimab (GOHIBIC)Critical COVID-19 (SARS-CoV-2-induced ARDS)Marketed (EUA)
VilobelimabPyoderma GangrenosumPhase 3
IzicopanHidradenitis SuppurativaPhase 2a
IFX002Chronic Inflammatory IndicationsPreclinical